Combination chemoradiotherapy with gemcitabine: Potential applications

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gemcitabine (Gemzar) is a novel deoxycitidine drug that has demonstrated promising single-agent activity in non-small-cell lung cancer and has been proven to be a potent radiosensitizer. Although the exact mechanism of the radiosensitizing effect is unknown, several studies have focused on the drug's effect on deoxyadenosine triphosphate (dATP) pool depletion or cell-cycle manipulation. A number of trials have evaluated this feature of gemcitabine by combining chemotherapy and radiation in various doses and schedules, and those studies are described in this article. Gemcitabine appears to be a promising agent to be combined with radiation therapy. However, further clinical trials are needed to define optimal doses, toxicity, and efficacy.

Original languageEnglish (US)
Pages (from-to)20-25
Number of pages6
JournalOncology
Volume14
Issue number7 SUPPL. 4
StatePublished - 2000

Fingerprint

gemcitabine
Chemoradiotherapy
Radiation-Sensitizing Agents
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Appointments and Schedules
Cell Cycle
Radiotherapy
Clinical Trials
Radiation
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Combination chemoradiotherapy with gemcitabine : Potential applications. / Choy, Hak.

In: Oncology, Vol. 14, No. 7 SUPPL. 4, 2000, p. 20-25.

Research output: Contribution to journalArticle

@article{e0c3d8f0afaa4cc9a9bf4f81b74523bb,
title = "Combination chemoradiotherapy with gemcitabine: Potential applications",
abstract = "Gemcitabine (Gemzar) is a novel deoxycitidine drug that has demonstrated promising single-agent activity in non-small-cell lung cancer and has been proven to be a potent radiosensitizer. Although the exact mechanism of the radiosensitizing effect is unknown, several studies have focused on the drug's effect on deoxyadenosine triphosphate (dATP) pool depletion or cell-cycle manipulation. A number of trials have evaluated this feature of gemcitabine by combining chemotherapy and radiation in various doses and schedules, and those studies are described in this article. Gemcitabine appears to be a promising agent to be combined with radiation therapy. However, further clinical trials are needed to define optimal doses, toxicity, and efficacy.",
author = "Hak Choy",
year = "2000",
language = "English (US)",
volume = "14",
pages = "20--25",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL. 4",

}

TY - JOUR

T1 - Combination chemoradiotherapy with gemcitabine

T2 - Potential applications

AU - Choy, Hak

PY - 2000

Y1 - 2000

N2 - Gemcitabine (Gemzar) is a novel deoxycitidine drug that has demonstrated promising single-agent activity in non-small-cell lung cancer and has been proven to be a potent radiosensitizer. Although the exact mechanism of the radiosensitizing effect is unknown, several studies have focused on the drug's effect on deoxyadenosine triphosphate (dATP) pool depletion or cell-cycle manipulation. A number of trials have evaluated this feature of gemcitabine by combining chemotherapy and radiation in various doses and schedules, and those studies are described in this article. Gemcitabine appears to be a promising agent to be combined with radiation therapy. However, further clinical trials are needed to define optimal doses, toxicity, and efficacy.

AB - Gemcitabine (Gemzar) is a novel deoxycitidine drug that has demonstrated promising single-agent activity in non-small-cell lung cancer and has been proven to be a potent radiosensitizer. Although the exact mechanism of the radiosensitizing effect is unknown, several studies have focused on the drug's effect on deoxyadenosine triphosphate (dATP) pool depletion or cell-cycle manipulation. A number of trials have evaluated this feature of gemcitabine by combining chemotherapy and radiation in various doses and schedules, and those studies are described in this article. Gemcitabine appears to be a promising agent to be combined with radiation therapy. However, further clinical trials are needed to define optimal doses, toxicity, and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0034218914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034218914&partnerID=8YFLogxK

M3 - Article

C2 - 10960941

AN - SCOPUS:0034218914

VL - 14

SP - 20

EP - 25

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 SUPPL. 4

ER -